elenbecestat

Small moleculeexperimental

Clinical trial activity

13 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
10
Phase 2
3
Phase 3
2
Phase 4
0

Earliest trial started Dec 1, 2010 (NCT01294540)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2016

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H]1OC[C@]2(c3cc(NC(=O)c4cnc(C(F)F)cn4)ccc3F)N=C(N)SC[C@H]12
Mol. weight
437.45 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • e2609
  • e2609
  • elenbecestat
  • elenbecestat

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03055962Phase 1Feb 14, 2017Eisai
NCT03036280Phase 3Dec 1, 2016Biogen, Eisai
NCT02956486Phase 3Oct 1, 2016Biogen, Eisai
NCT02859207Phase 1Aug 1, 2016Eisai
NCT02322021Phase 2Nov 1, 2014Biogen, Eisai
NCT02222324Phase 1Aug 1, 2014Eisai
NCT02207790Phase 1Jul 1, 2014Eisai
NCT02055703Phase 1Jan 1, 2014Eisai
NCT01975636Phase 1Jun 1, 2013Eisai
NCT01716897Phase 1Oct 1, 2012California Clinical Trials, Eisai
NCT01600859Phase 1Jul 1, 2012California Clinical Trials, Eisai, Parexel
NCT01511783Phase 1Dec 1, 2011Compass Research, Eisai
NCT01294540Phase 1Dec 1, 2010Eisai, Loma Linda University
Showing 13 of 13 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
EisaiFor profit131332010
BiogenFor profit3022014
California Clinical TrialsFor profit2012012
Compass ResearchFor profit1012011
Loma Linda UniversityAcademic/Hospital1012010
ParexelFor profit1012012
6 organizations
Page 1 / 1